ESR1 and carcinoma: At present, clinicians typically classify carcinomas into five subtypes (luminal A, luminal B HER2−, luminal B HER2+, HER2, and TN) on the basis of histologic and molecular characteristics, which notably include expression of the estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67.